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: O cancro da próstata (CaP) é uma doença heterogénea, sendo, 
atualmente, a neoplasia maligna não-cutânea mais comum em homens nos países 
desenvolvidos e a sexta principal causa de morte por cancro a nível mundial. O 
conhecimento sobre o processo de iniciação e progressão da doença é ainda 
limitado, sendo reconhecida a necessidade de desenvolver e aperfeiçoar métodos 
inovadores para apoio à deteção precoce, diagnóstico e decisão terapêutica. A 
descoberta da metilação do DNA como mecanismo de regulação génica essencial 
à homeostasia celular e cuja desregulação constitui um evento comum na 
carcinogénese, tem possibilitado uma maior compreensão da biologia do CaP. De 
facto, diversos estudos revelaram que a alteração dos padrões de metilação nos 
promotores dos genes ocorre em etapas precoces do desenvolvimento do CaP. Os 
microRNAs constituem um outro mecanismo de regulação da expressão génica e 
cuja desregulação está também relacionada com a carcinogénese. A expressão 
desta classe de RNAs não codificantes de cadeia curta pode ser, igualmente, 
regulada por meio da metilação do DNA. Contudo, o potencial desta alteração 
como biomarcador de CaP não foi, até à data, cabalmente explorado. 
: Determinar, em doentes de CaP, o potencial como biomarcador 
diagnóstico e prognóstico da quantificação da metilação de regiões promotoras de 
microRNAs recentemente identificados. 
 : A análise prévia através de HumanMethylation450 
BeadChip permitiu a identificação dos dinucleótidos CpGs mais diferencialmente 
metilados localizados em regiões promotoras de microRNAs. A partir desta análise, 
os níveis de metilação das regiões promotoras de miR-34b/c, miR-129-2, miR-152, 
miR-193b, miR-663a e miR-1258 foram selecionados para validação através de 
qMSP, numa série alargada de tecidos prostáticos. Os níveis de metilação das 
regiões promotoras destes microRNAs foram igualmente analisados em amostras 
tumorais e não tumorais de bexiga e rim a fim de avaliar a sua especificidade para 
CaP. Posteriormente, os níveis de metilação das regiões promotoras de miR-34b/c, 
miR-193b e miR-1258 foram avaliados em sedimentos urinários, e os de miR-34b/c 
e miR-129-2 em biópsias prostáticas, para determinação do seu valor diagnóstico 
e prognóstico, respetivamente. 
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: Foi confirmada a elevação significativa dos níveis de metilação 
dos promotores dos microRNAs candidatos (selecionados a partir do array) em CaP 
comparativamente com tecido prostático normal. Excetuando miR-152, todos os 
candidatos apresentaram valores de AUC superiores a 0.90 nesta série de 
amostras. O miR-193b e miR-1258 demonstraram os melhores resultados, com 
valores de AUC=0.96 e AUC=0.99, respetivamente. Globalmente, níveis de 
metilação mais elevados associaram-se a estadio patológico mais avançado, tendo 
os níveis de metilação de miR-129-2 associado com grau combinado de Gleason 
mais elevado. Quando testados em amostras de tecido vesicais e renais, quer 
normais, quer neoplásicos, o miR-129-2 e miR-663a apresentaram níveis de 
metilação mais elevados em tumores vesicais comparativamente a CaP. Dos 
candidatos testados em sedimentos urinários, o miR-193b demonstrou melhor 
desempenho, com AUC=0.96, 91.6% de sensibilidade e 95.7% de especificidade. 
Numa série de amostras de biópsias prostáticas, níveis de metilação mais elevados 
do miR-129-2 demonstraram ser preditores independentes de menor sobrevivência 
específica e livre de doença. 
: A validação dos resultados do array confirmou a quantificação 
da metilação dos promotores de miR-34b/c, miR-193b e miR-1258 como 
biomarcadores específicos de CaP em amostras de tecido. Para efeitos de deteção 
precoce, sendo urina a amostra ideal, a quantificação dos níveis de metilação do 
promotor de miR-193b demonstrou um desempenho comparável ao dos melhores 
biomarcadores epigenéticos para CaP até à data descritos. No que respeita à 
avaliação do valor prognóstico, elevados níveis de metilação do promotor de miR-
129-2 demonstraram ser preditores independentes de um menor intervalo de 
tempo até recorrência bioquímica e mortalidade devida à neoplasia, sendo apenas 
superado pelo estadio clínico. 
: Neste estudo, foi demonstrado que a quantificação dos níveis 
de metilação dos promotores dos miR-193b e miR-129-2 tem potencial utilidade 
como biomarcadores de diagnóstico e prognóstico, respetivamente. Assim, 
poderão constituir ferramentas úteis no apoio à avaliação clínica e decisão 
terapêutica de pacientes com CaP. Contudo, a confirmação deste valor clínico 
requer validação em séries independentes. 
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: Prostate cancer (PCa) is a heterogeneous disease that 
constitutes the most common cancer in men from western countries and the sixth 
leading cause of death by cancer among men worldwide. Current knowledge about 
its onset and progression is still limited and better tools for improved diagnosis 
and therapeutic decision-making are needed. Insight into DNA methylation has 
shed new light on PCa biology. This gene regulation mechanism is essential for 
cellular homeostasis and its alteration is common in cancer. Indeed, altered 
patterns of DNA methylation occur at early steps of PCa development, including 
those occurring at gene promoter regions. MicroRNAs are a class of small non-
coding RNAs involved in gene expression regulation and its deregulation has been 
implicated in tumorigenesis. MicroRNA expression regulation by DNA methylation 
has been previously reported but its potential use as PCa biomarker has not been 
systematically explored. 
 
: To assess the diagnostic and prognostic biomarker potential of 
quantitative promoter methylation of newly identified microRNAs in PCa patients. 
 
: HumanMethylation450 BeadChip-based analysis 
previously enabled the identification of the most differentially methylated CpGs in 
known microRNA promoter regions. From this analysis, methylation levels in miR-
34b/c, miR-129-2, miR-152, miR-193b, miR-663a e miR-1258 promoter regions 
were selected to be validated by qMSP in a large set of tissue samples. Promoter 
methylation levels of those microRNAs were also assessed in bladder and kidney 
non-tumorous and tumorous samples, to determine its PCa-specificity. Then, 
promoter methylation levels of miR-34b/c, miR-193b and miR-1258 were evaluated 
in urine sediments and miR-34b/c and miR-129-2 in biopsy samples to test for 
diagnostic and prognostic value, respectively. 
 
: Higher promoter methylation levels in PCa compared to normal 
prostate were confirmed for all six candidate microRNAs selected from the array. 
Except for miR-152, all candidates displayed AUC values higher than 0.90 in this 
sample set. MiR-1258 and miR-193b disclosed the best performance with 
AUC=0.99 and AUC=0.96, respectively. Higher methylation levels of all candidates, 
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excepting miR-152, correlated with higher pathological stage. Moreover, higher 
miR-129-2 methylation levels also correlated with a higher Gleason grade. When 
tested in bladder and kidney tissues (normal and neoplastic), miR-129-2 and miR-
663a showed higher methylation levels in bladder cancer compared to PCa. Of the 
candidates tested in urine samples, miR-193b showed the best performance, with 
AUC=0.96, 91.6% sensitivity and 95.7% specificity. In a prostate biopsy sample set, 
higher miR-129-2 methylation levels independently predicted for shorter DSS and 
DFS. Although a similar trend was apparent for miR-34b/c, it did not achieve 
statistical significance. 
 
: In the initial validation of the array results, miR-34b/c, miR-
193b and miR-1258 promoter methylation levels were shown to be PCa-specific 
biomarkers in tissues, emerging as promising candidates for subsequent testing. 
For early diagnosis purposes, urine is an ideal sample and miR-193b quantitative 
promoter methylation demonstrated biomarker performance similar to the best 
epigenetic biomarkers thus far reported for PCa. Concerning assessment of 
prognosis, high miR-129-2 promoter methylation levels independently predict for 
shorter time to biochemical recurrence and decreased disease-specific survival. Its 
performance as prognostic biomarker was only surpassed by clinical stage. 
 
: Herein, we demonstrate that quantitative miR-193b and miR-
129-2 promoter methylation have potential clinical usefulness as early diagnostic 
and prognostic biomarkers, respectively. Nevertheless, these findings require 
validation in larger and independent sample sets. 
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The prostate is a retroperitoneal organ that surrounds the bladder neck and 
the urethra, being posteriorly separated from the rectum by the Denonvillier’s 
fascia [5, 6]. It has a pear-like shape, with its base at the bladder neck and the apex 
at the urogenital diaphragm, weighting about 20g in the adult male with a volume 
around 25cm
3 
[5-7]. 
The prostate, as an exocrine organ, consists of glands secreting a fluid that 
comprises the bulk of the seminal emissions and is emptied into the urethra. Due 
to its location and function, the development of prostatic cancer as well as its 
treatment options brings risks to the sexual, urinary and bowel functions [7]. 
Anatomically, the prostate gland is a heterogeneous organ. Throughout the 
twentieth century, the regional anatomy of the prostate did not gather consensus 
between investigators. In 1981 McNeal proposed the currently accepted model of 
zonal organization [5, 8]. According to this model, four basic anatomic regions can 
be identified. The peripheral zone constitutes over 70% of the glandular component 
and is located at the lateral and posterior sides of the organ. The vast majority of 
carcinomas, as well as the other pathologies affecting this organ, arise from this 
region [8]. The central zone represents 25% of the glandular prostate and is located 
posteriorly to the urethra surrounding the ejaculatory ducts. There are marked 
architectural differences between the central and peripheral zones, suggesting 
different biological roles [8]. The transition zone is centrally located, surrounding 
the prostatic urethra. Finally, the anterior fibromuscular stroma (AFMS) which is a 
band of fibromuscular tissue, contiguous with the bladder’s smooth muscle and 
the external sphincter, forming the anterior surface of the gland as a thick, non-
glandular layer [7, 8]. A partial capsule encloses the posterior and lateral sides of 
the prostate while the anterior and apical surfaces are covered by the AFMS [7].  
Concerning the gland’s histology, its architecture is that of a branched duct 
gland embedded in a fibromuscular stroma [5]. Prostate epithelium is composed 
of two layers of cells: secretory luminal cells (PSA producing and androgen receptor 
positive) and basal cells, with rare neuroendocrine cells being present as well [7, 
9]. 
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Prostate cancer (PCa) is the most common male cancer in western countries 
[10]. PCa is an age-related and a very heterogeneous disease, both genetically as 
well as clinically, ranging from relatively indolent to highly aggressive tumors. This 
disease is typically asymptomatic, thus leading to commonly late diagnosis which, 
in turn, impairs not only prognosis but also therapeutical strategies [11]. 
Currently, PCa is a major health concern in western countries standing as 
the second most common cause of cancer and the sixth leading cause of death by 
cancer among men, worldwide [12]. The burden brought by this malignancy is 
increasing simply due to the global population’s growth and aging [13]. In 2012, 
the number of PCa cases diagnosed worldwide accounted to approximately 15% of 
all new cases of cancer diagnosed in men [14]. The American Cancer Society yearly 
predictions for 2015 suggest that prostate cancer alone will account for 26% (about 
220,800) of newly diagnosed cancer cases and 9% (27,540) deaths in men in the 
USA alone [15]. 
Geographically, PCa incidence and mortality rates have a highly 
heterogeneous distribution. Specifically, incidence rates vary more than 25-fold 
worldwide with the highest rates being observed in North-America, Europe and 
Oceania mainly due to wide use of PSA based screening [12]. Temporal trends are 
influenced by usage of PSA testing as a diagnostic tool. Soon after the introduction 
of PSA testing, incidence rates rapidly arose followed by a sharp decline. This 
pattern was particularly evident in the USA, Canada, Australia and Nordic countries. 
On the other hand, in countries such as the UK and Japan, with a low and gradual 
increase in the prevalence of PSA-testing, rates continue to increase slightly [12]. 
Death rates have been declining in high-income countries, in part due to 
improvements in treatment with curative intent. The role of PSA-testing in this trend 
remains elusive with studies in Europe and the USA reporting little to no gains. On 
the other hand, mortality rates are increasing rapidly in Asian, central and eastern 
European countries [12, 13]. 
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Currently, there are only three risk factors well-established for PCa, namely: 
age, race and family history. However, smoking and increased body-mass have also 
been found to be associated with PCa, particularly with more aggressive tumors. 
Other factors, including exposition to ionizing or ultraviolet radiation,  endogenous 
hormones and urinary tract infections were suggested to be linked to PCa, but still 
require additional studies for confirmation [16]. 
Age is the most important factor in PCa. In unscreened populations, PCa has 
the steepest age-dependent incidence curve, with an increased slope in the seventh 
decade of life [16]. Similarly to other epithelial malignancies, PCa is a disease 
mainly related to aging, commonly afflicting men above 65 years of age with 
diagnosis earlier than this age being rare and incidence peaking between 70 and 
74 years old [16, 17]. Cases in men with less than 50 years of age are extremely 
uncommon, accounting for 0.1% of all cases [17]. 
Incidence and mortality rates vary significantly between races. Compared to 
their Caucasian counterparts, African-american individuals have a younger median 
age of diagnosis, 58% higher incidence and 144% greater mortality. On the other 
hand, individuals with Hispanic ancestry show 14% lower incidence and 17% lower 
mortality. Individuals of Asian origin appear to have a lower risk to develop the 
disease. For instance, Asian, Indians and Pakistanis living in the USA have a 
standardized incidence ratio of 0.54 when compared to American Caucasian 
populations [16]. 
Men with strong family history of PCa have two to four times higher 
incidence, when compared with control groups. This risk is particularly higher in 
patients with a first degree relative who was afflicted with the disease and also with 
relatives that were diagnosed at younger ages [18]. Association with X-chromosome 
has also been suggested. It has been found that individuals with a brother that 
harbored the disease have higher risk of developing this malignancy comparing to 
individuals in which the father was a PCa patient [18]. Although rare, BRCA2 
mutations increase by 8.6 times the risk of developing the disease at an age below 
65 years and are correlated with a more aggressive behavior [16, 18]. Other 
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mutations that confer higher risk, albeit rare, have been reported in BRCA1, 
HOXB13, NSB1 and CHEK2 genes [16]. 
The adoption and effectiveness of a screening program for PCa is still a 
matter of debate [12, 19]. In many countries, screening programs based on PSA 
testing in combination with digital rectal examination have been introduced [19]. 
A suspicion of PCa usually arises on the basis of DRE and PSA levels although a 
definitive diagnosis is always dependent in cytological or histological analysis from 
core biopsies or surgical specimens [20]. 
Since most prostate cancers are located in the peripheral zone, their 
detection is possible by DRE once their volume is 0.2mL or higher. In about 18% of 
the patients, PCa detection is made by DRE, irrespective of the patients PSA values. 
Abnormal DRE is associated with a higher Gleason score and, thus, is an indication 
for prostate biopsy [20].  
Usage of PSA as a serum marker revolutionized PCa detection. This enzyme 
is produced by prostatic epithelial cells and is organ, but not cancer, specific. 
Therefore, PSA serum levels may be increased in benign conditions such as BPH 
and prostatitis [20, 21]. The PSA value is a continuous parameter and a higher PSA 
value represents a higher likelihood of PCa existence. Currently, a positive PSA test 
with a value greater than 3 to 4 ng/mL is indicative for prostate biopsy [19, 20].  
The standard way to obtain material for histopathological examination is 
ultrasound-guided transrectal or transperineal 18G core biopsy [20]. On the 
histological analysis of the cores obtained, the glands are typically smaller and are 
lined by a single layer of cuboidal or low columnar cells. They have a more crowded 
aspect and are devoid of the basal cell layer that is present on the normal 
architecture and also in the benign afflictions of the gland. Nuclear size is increased 
and one or two nucleoli may be present [6].  
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Prostatic adenocarcinomas are often 
multifocal and heterogeneous neoplasms [20]. In 
this context, the Gleason Score was developed. 
Gleason’s grading evaluates the architectural 
features of the cancer glands, categorizing them 
into five distinct patterns from well to poorly 
differentiated. The Gleason Score is then 
obtained as the sum of the two most common 
growth patterns observed in the specimen, 
incorporating both a primary (the most prevalent) 
grade and a secondary (next most prevalent) 
grade, and ranging from 2 (1+1) to 10 (5+5) [5, 
7]. 
Both in radical prostatectomy specimens 
and needle biopsy samples, the Gleason Score is 
currently the strongest prognostic factor [20]. 
Albeit being globally accepted and used, 
the Gleason system displays several limitations. 
In particular, the Gleason grading is observer dependent, varying with the 
experience of the pathologist. Moreover, nowadays, most of the diagnosed patients 
fall in the Gleason 6-7 category, an intermediate prognostic range that limits the 
usefulness of the 10-point scale [11]. On the other hand, in neoplasms that have a 
minor high grade component, a tertiary Gleason Score may be reported, since it 
carries significant prognostic information [7]. Although the Gleason Score is the 
most powerful prognostic factor, other features must be taken into account during 
histopathological evaluation such as the presence of extracapsular invasion, 
perineural invasion, surgical margin status, lymph node status and seminal vesicle 
invasion [11]. 
Cancer staging is a key factor to ascertain prognosis and determining 
treatment. Several cancer staging systems are used worldwide and the most 
clinically useful is the tumor node metastasis or TNM system [22]. This system 
classifies cancers by the size and extent of the primary tumors (T), the presence of 
Figure 1 - The Gleason grades 
range from closely packed and 
uniform glands (grade 1) to 
almost complete loss of glandular 
differentiation (grade 5). Adapted 
from [1]. 
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involvement of regional lymph nodes (N) and presence or absence of distant 
metastases (M) [22]. 
There are two types of staging: the clinical and pathological. In prostate, 
clinical staging is determined mainly from data collected by DRE, TRUS and 
magnetic resonance imaging, although PSA level is also a factor taken into account. 
Clinical staging remains unchanged apart from the pathological stage which is, in 
turn, ascertained after radical prostatectomy and its data is provided by 
macroscopic and microscopic observation of the surgical specimen and dissected 
lymph nodes [23]. 
In PCa, T-staging is the first and most important since the distinction 
between organ confined (T1-T2) and extraprostatic disease (T3-T4) is the most 
impactful aspect on treatment decisions [20]. On the other hand, N-staging should 
only be pursued in cases where the potential findings will impact treatment 
decisions, particularly in patients where curative treatments are planned. The gold 
standard for N-staging is surgical lymphadenectomy although computer 
tomography and magnetic resonance imaging may be used [20]. 
 
Table 1 - Pathological staging of prostate cancer. Adapted from [19]. 
Primary tumor cannot be assessed 
No evidence of primary tumor 
Clinically unapparent tumor neither palpable nor visible by Imaging 
Tumor incidental histologic finding in 5% or less of tumor resected 
Tumor incidental histologic finding in more than 5% of tumor resected 
Tumor identified by needle biopsy 
Tumor confined within prostate gland 
Tumor involves one half of one side or less 
Tumor involves more than one half of one lobe but not both lobes 
Tumor involves both lobes 
Tumor extends through prostate capsule 
Extracapsular extension (unilateral or bilateral) 
Tumor invades seminal vesicle(s) 
Tumor is fixed or invades adjacent structures other than seminal vesicles, 
such as: external sphincter, rectum, bladder, levator muscles, and/or pelvic 
wall 
 9 
 
Currently, the difference between PCa incidence and death rates is quite 
considerable. Many autopsy studies showed that 60-70% of aged men who die from 
different causes, harbor histological PCa, with an estimated 10-15% of these having 
a Gleason score of 7 or higher. Indeed, it is estimated that about 15-20% of men 
are diagnosed with PCa during their lifetime, but only 3% of those men die from it. 
At the same time, the incidence of small localized tumors is increasing, essentially 
as a result of early screening procedures. Therefore, there is a number of men who 
do not need aggressive and definitive forms of treatment. On the other hand, in 
patients with limited co-morbidities and limited life-expectancy, the need of a 
Organ confined 
Unilateral, involving one-half of one side or less 
Unilateral, involving more than one-half of one side but not both sides 
Bilateral disease 
Extraprostatic extension 
Extraprostatic extension or microscopic invasion of bladder neck 
Seminal vesicle invasion 
Invasion of rectum, elevator muscles and/or pelvic wall 
Regional lymph nodes were not assessed 
No regional lymph node metastasis 
Metastasis in regional lymph node(s) 
Cannot be assessed 
No positive regional nodes 
Metastasis in regional node(s) 
No distant metastasis 
Distant metastasis 
Non-regional lymph node(s) 
Bone(s) 
Other site(s) with or without bone disease 
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definitive treatment is questionable. Thus, the risk of overtreatment, ie, treatment 
of a disease that will not pose a threat to the patient’s well-being during his lifetime, 
is one of the major issues of PCa screening [24, 25]. As a result, two different 
approaches have been proposed: active surveillance and watchful waiting. Active 
surveillance was developed aiming to reduce overtreatment in patients with 
clinically confined low-risk PCa that are surveilled, but curative treatment is still 
available when needed. Therefore, active surveillance should only be applied to 
very carefully selected low-risk patients, specifically with PSA levels below 
10ng/mL, with a Gleason score lower than 7 and clinical stage of cT1c to cT2a [24, 
26].  
Watchful waiting comes from the knowledge that PCa is, usually, a slow 
progression disease. It is a strategy to avoid radical treatment in patients with 
serious co-morbidities from other diseases and/or less than a 5-year life 
expectancy [24]. Thus, tumor stage is of high importance, with tumor stage 3 
having very low survival rates and stages 1 and 2 showing a better 10-year cancer-
specific survival [24]. 
Concerning active treatment, radical prostatectomy (RP) and radiation 
therapy are the most common approaches for localized PCa. Active treatments are 
largely curative, despite the concern about overtreatment [24, 26].  
RP is the surgical treatment for PCa. This surgery consists in removing the 
whole gland, the seminal vesicles and enough surrounding tissue to ensure 
negative margins. This procedure may be accompanied by bilateral pelvic lymph 
node dissection. In patients with localized disease and life expectancy higher than 
10 years, the goal of this procedure is curative treatment with the preservation of 
continence and, if possible, potency. RP remains the only treatment for localized 
disease that showed cancer-specific benefit in comparison with watchful waiting in 
a prospective randomized trial. However, it must be taken into account that, so far, 
the benefit of RP over watchful waiting has only been observed in patients with 
intermediate or high-risk PCa [20]. 
Radiation therapy is a valid alternative to surgery as a curative therapy. 
External radiation beam therapy provides a quality of life comparable to surgery. 
Transperineal low-dose or high-dose rate brachytherapy is also widely used. 
Curiously, there have been no randomized studies comparing the radical 
prostatectomy with radiation therapy in localized disease [20]. 
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Metastatic PCa has a poor prognosis, although it depends highly on the 
extent of the disease. Minimal metastatic disease has been defined as involvement 
of the axial skeleton and lymph nodes while extensive disease involves the viscera 
and/or appendicular skeleton [25]. 
For more than half a century, androgen deprivation therapy has been the 
standard treatment for patients with metastatic disease. This therapy originated 
from the demonstration by Huggins in 1941 that orchiectomy or estrogens could 
induce dramatic remissions in advanced PCa. Posteriorly, it was found that 
sustained LHRH administration leads to a down-regulation of LH secretion which in 
turn causes a decline in the levels of testosterone [25]. 
Nevertheless, the median duration of response to ADT is, approximately, 18-
24 months, after which most cases progress to a form of disease called castration-
resistant prostate cancer. This late form of the disease is extremely aggressive 
rendering a rather grim prognosis with some studies reporting that without 
treatment median survival time is about 9 to 21 months [27]. 
Due to the complexity of PCa as a disease and the multiple variables that 
affect its outcome, the prediction and adequate management of each patient is still 
one of the problems in clinical practice. An approach to this difficulty has been the 
development of several multivariable models for disease progression prediction, 
based in the clinico-pathological information available at the time of diagnosis [28]. 
Many of those models have been in the form of nomograms, one of the most 
prominent being CAPRA score [29]. 
Proposed by Cooperberg et al. in 2005, this nomogram aims to predict the 
pre-operative probability of biochemical-recurrence-free survival after radical 
prostatectomy in patients with clinically localized prostate cancer [29]. This model, 
based in the PSA level, Gleason score, clinical stage, percentage malignant cells in 
biopsy core samples and patients’ age at diagnosis to generates a numerical value 
from 0 to 10. Values between 0-2, correspond to  low-risk tumors, 3 to 5 
intermediate and tumors above 5 are considered to have a high-risk for biochemical 
relapse [30].  
Different validation studies have confirmed its ability to correctly predict 
biochemical recurrence at 3 years after radical prostatectomy. Some studies 
reported that this ability can be extended to 5 years, although this is still 
controversial as some authors argue that this model significantly under-predicts 
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biochemical recurrence 5 years after RP [29]. Moreover, CAPRA score has been also 
shown to accurately predict cancer-specific mortality and metastasis development 
in patients subjected to other therapeutic strategies, namely radiation therapy, 
androgen deprivation or even without treatment (watchful waiting /active 
surveillance) [30]. 
In an attempt to improve 5-year predictive value, additional predictive 
variables were added to the original nomogram. This revised score also includes 
surgical margins of the surgical specimen, seminal vesicle invasion, extracapsular 
extension and lymph node invasion [31]. This revised model appears to improve 
the original’s prediction capabilities although further validation is needed [29]. 
Epigenetics is currently defined as the mechanisms that initiate and maintain 
heritable patterns of gene function and regulation in a heritable manner without 
interference in the genome sequence, hence the name: epi – an ancient Greek word 
meaning “what stays beyond” – genetics [32]. These mechanisms contribute to the 
cell diversity observable inside a single organism, despite all cells keeping the same 
genetic information [33].  
Currently, three epigenetic mechanisms are known: DNA methylation, 
histone covalent modification and non-coding RNAs. Together, these mechanisms 
constitute the epigenetic code, modulating the expression of the mammalian cell 
genome through developmental stages and various diseases, including cancer [4]. 
Epigenetics is an emergent field of research, which in the last two decades 
expanded rapidly, bringing new insights into cancer research [34]. Various 
discoveries in vitro, in vivo and human clinical and epidemiological studies have 
challenged the classical view of cancer as a genetic disease, and as such, epigenetic 
deregulations are now considered a hallmark of cancer [32, 35]. 
The most widely studied epigenetic mechanism, DNA methylation was the 
first epigenetic alteration to be associated with cancer [32, 35]. In mammals, DNA 
methylation occurs mainly by the addition of a methyl group (CH3) to the 5’ carbon 
of a cytosine nucleotide preceding guanine, originating 5-methylcytosine (5mC) in 
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CpG dinucleotides [36]. Additionally, this modification may interfere with the 
binding of transcription factors [4]. 
The cytosine methylation reaction is catalyzed by the DNMT family of 
enzymes, particularly DNMT1, DNMT3A and DNMT3B being S-adenosyl-methionine 
the methyl group donor. It is known that DNMT3A and DNMT3B are responsible for 
establishing DNA methylation patterns during embryo development while DNMT1 
is involved in the maintenance of these patterns [4]. 
CpG dinucleotides are not randomly nor evenly distributed throughout the 
genome. Instead, they tend to be concentrated either in short CpG-rich fragments 
or in long repeats called “CpG islands” or CGI [35]. There two criteria required to 
consider a certain DNA stretch as a CGI, namely to have more than 200 bases with 
a CG content of at least 50% and a ratio of expected CpG frequency of at least 0.6 
[37]. About 60% of human gene promoters contain CGI and DNA methylation in CGI 
within gene promoters correlates with condensed chromatin structure leading to 
gene silencing either inhibiting transcription factor binding or by attracting DNA-
binding proteins which in turn recruit repressive complexes [38]. However, 
methylation within the gene body does not block gene’s transcription but instead 
appears to promote transcription elongation and impacts in splicing. Moreover, 
methylation in repetitive regions, such as centromeres, is crucial for chromosomal 
stability. Strikingly 70-80% of these regions are methylated in the human genome 
[39]. 
During the development and differentiation stages, CpG islands are not 
methylated. However, in 
normal, mature tissues, 
some CpG islands in 
promoter regions can be 
methylated leading to 
permanent silencing of 
target genes. Therefore, 
the methylation pattern of 
a given tissue is acquired 
during differentiation and 
this pattern is tissue-
specific [33, 35]. 
Figure 2 - Global changes in DNA methylation from normal to 
cancer cells. In normal conditions, gene promoters usually are not 
methylated allowing gene expression. In cancer, methylation 
patterns are altered, with promoter hypermethylation and 
hypomethylation of gene bodies and noncoding regions. 
Adapted from [4]. 
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These specific methylation patterns may change in disease. These changes 
can be divided in into three categories: promoter-specific hypermethylation, global 
hypomethylation and loss of imprinting when comparing a pathological tissue with 
its normal counterpart [32].  
DNA hypermethylation is generally the gain of methylation in regions where, 
in normal conditions, there is no methylation and has been associated with loss of 
gene expression, occurring fundamentally on tumor suppressor genes [32].   
Hypomethylation is the loss of methylation and happens mainly in genome-
wide regions, being a well-established trait of cancer cells. DNA hypomethylation 
in cancer was discovered before DNA hypermethylation and its effects have greater 
impact [36]. It occurs in many gene-poor areas containing repetitive elements, 
retrotransposons leading to genome instability and causing translocations and 
chromosome rearrangements [32, 36].  
Loss of imprinting consists in the loss of allele-specific monoallelic 
expression of particular genes because of aberrant hypomethylation in one of the 
two parental alleles [32]. A classic example is the loss of imprinting at the IGF2 
locus in colorectal carcinoma [40]. 
Aberrant methylation has been established as a hallmark of cancer, both at 
individual genes and at a global genomic scale [41, 42]. The decreased levels of 
methylation in tumors comparatively to their normal-tissue counterparts was one 
of the first epigenetic alterations discovered in human cancer. It is also known that, 
during the progression of a neoplasm from a benign proliferation of cells to a 
malignant and invasive cancer, the degree of genomic hypomethylation increases 
[36]. In turn, these changes may favor mitotic recombination causing deletions and 
translocations, and promote chromosome recombination [43]. 
As previously stated, hypermethylation of CpG islands in the promotor 
region of a gene may lead to its inactivation. In many cancers, the inactivation of 
tumor-suppressor genes by this mechanism is a major event. However, 
hypomethylation is a general feature of cancer, whereas CGI hypermethylation is 
highly specific to each cancer type, to the point that every tumor type may be 
assigned a specific DNA “hypermethylome”. Inactivation of tumor-suppressing 
genes by methylation occurs both in sporadic as well as in hereditary cancers where 
hypermethylation may be the second hit in Knudson’s two-hit model [43]. 
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So far, the reason why some CGIs are methylated in some cancers and not 
in others remains unknown. Some DNA sequences show “opposite” methylation 
levels depending of the type of cancer such as NBL2 and D4Z4, two DNA repeats 
that are hypermethylated in certain cancers and hypomethylated in others. Another 
case is the hypomethylation of the justacentromeric Sat2 repeat, which is observed 
in gastric and breast cancer but not in colon cancer [36]. 
Concerning PCa, several methylation abnormalities have already been 
reported. Global hypomethylation has been observed in PCa which may have the 
already described effects in these cancer cells. Moreover, this hypomethylation is 
considerably higher in patients with metastatic disease when compared with non-
metastatic neoplasms [4]. Gene specific hypomethylation has also been described 
in PCa affecting genes involved in a wide range of cell functions: from invasion, to 
metastasizing properties, cell cycle control and activation of carcinogens [4]. 
Gene hypermethylation has been widely studied and found to occur at a 
large scale. Hypermethylated genes in PCa are involved in many biological 
processes such as DNA repair (GSTP1), signal transduction (RASSF1A), cell adhesion 
(E-cadherin, CD44 and galectins), hormonal response (RARβ , AR and ER), apoptosis 
(death-associated protein kinase), invasion, metastasis and cell cycle control [4]. 
In the eukaryotic cell, DNA is packed in the nucleus. However, it must be 
tightly regulated and then copied during cell division. Vital to both packaging and 
overseeing DNA stability are the histones. About 147 base pairs of DNA wrap 
around an octamer of histones which consist of two copies of H3, H4, H2A and 
H2B, forming the building block of chromatin, the nucleosome. Another histone 
protein, H1, binds to both the nucleosome and to the “linker DNA” thus keeping in 
place the DNA wrapped around the nucleosome [44]. 
Chromatin is a dynamic macromolecule with two distinct domains: 
heterochromatin and euchromatin, defined by the level of compaction and 
consequent genomic functions. Therefore, euchromatin is a more loose 
conformation allowing a higher level of transcription whereas heterochromatin 
(either constitutive or facultative) is the more condensed form and is typically 
transcriptionally repressive [44]. 
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Chromatin organization and regulation is achieved by numerous factors. Of 
particular interest are histone post-translational modifications. Typically, these 
occur in the C- and N- terminal domains, which protrude from the core of the 
nucleosome. However, a significant amount occur in the fold or globular domains 
of the protein thus interfering in the histone-histone and histone-DNA interactions. 
Several post-transcriptional modifications have been reported such as methylation, 
acetylation, phosphorylation, deamination, ubiquitylation, glycosylation and 
sumoylation [45]. 
Globally, each post-transcriptional modification confers different effects. 
Particular marks, such as acetylation traditionally leads to transcriptional activation 
[46]. Histone methylation, for instance, is a more complicated field than acetylation 
leading either to repression or promotion of gene transcription depending of the 
target residue and even of the degree of its methylation [47]. Behind all these marks 
and their effects is the cellular machinery that creates and maintains these patterns. 
The enzymes that constitute this machinery are usually classified into writers, 
laying the marks on the histones; readers, which recognize the marks; and erasers, 
the ones that remove the marks. The distinct patterns of histone post-translational 
modifications is called the “histone code” and, together with DNA methylation, 
plays a huge role in gene transcription [48]. 
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Table 2 - Examples of histone marks, their enzymes and their effect. Lysine (K), arginine (R), serine 
(S), threonine (T). Transcriptional activation (Ta), transcriptional repression (Tr), DNA repair (R), and 
DNA replication (Rep). Adapted from (48). 
H2A K5 Tip60, Hat1, P300/CBP Ta, R 
H2B 
K12 ATF2, P300/CBP Ta 
K20 P300 Ta 
H3 
K9 Gcn5, SRC-1 Ta, R 
K14 
Gcn5, PCAF, Tip60, SRC-1, 
hTFIIIC90, TAF1, p300/ Gcn5, 
Esa1, Elp3, Hpa2, TAF1, Sas2 
Ta, R, 
Rep 
K18 P300, CBP/Gcn5 (SAGA) Ta, R 
K23 P300, CBP/Gcn5 (SAGA), Sas3 Ta, R 
K27 Gcn5 Ta, R 
H4 
K5 
Hat1, Tip60, ATF2, p300/Hat1, 
Esa1, Hpa2 
Ta, R, 
Rep 
K5 
Gcn5, PCAF, Tip60, ATF2, 
p300/Esa1, Elp3 
Ta, R, 
Rep 
K12 Hat1, Tip60/Hat1, Esa1, Hpa2 
Ta, R, 
Rep 
K16 
MOF, Gcn5, Tip60, ATF2/Gcn5, 
Esa1, Sas2 
Ta, R 
H1 K26 EZH2 Tr 
H3 
K4 
MLL4, SET1, MLL1, SET7/9, 
MYD3/Set1 
Ta 
K9 SUV39H1, ESET/SETDB1 Tr 
K27 EZH2, G9A Ta, Tr 
K36 HYPB, NSD1/Set2, S.c. Ta 
K20 PR-SET7, SUV4-20/SET9 Ta, Tr, R 
H2A T119 NHK-1 Tr, R 
H2B S14 Mst1 R 
H3 
S10 
TG2, Aurora B, MSK1, 
MSK2/Snf1 
Ta 
T11 Dlk/ZIP Ta 
H4 S1 CK1 R 
H2A K119 Ring 1b Ta, R 
H2B K120 RNF 20/40 Ta, R 
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MicroRNAs (also called miRs or 
miRNAs) are a class of small non-coding 
RNAs with a length of 19-25 nucleotides 
[49]. They are encoded in the genome in 
diverse contexts, either expressed in 
intronic or intergenic transcripts that 
encode a single microRNA hairpin 
precursor or in clusters of multiple 
precursors [50].  
These small sequences are 
transcribed, mostly, by RNA polymerase 
II as long primary transcripts 
characterized by hairpin structures (pri-
microRNAs) and then processed in the 
nucleus by RNAse III Drosha into 70-100 
nucleotides long pre-microRNAs. These 
molecules are then exported to the 
cytoplasm by an Exportin 5-mediated 
mechanism. There, another RNAse III, 
Dicer, acts in complex with TRBP, 
generating a dsRNA with approximately 
22 nucleotides of length, called miRNA/miRNA*, including the mature miRNA 
guide, and the complementary passenger strand, the miRNA*. Many publications 
refer to these two strands as miR-5p and miR-3p, respectively. According to 
thermodynamic properties, one of the strands is selected as guide strand, whilst 
the other is usually degraded. Recent evidence suggests that miRNA* or miR-3p 
may not be just a byproduct of microRNA biogenesis but may also be selected as 
the functional strand and therefore play a biological role [3]. Finally, the mature 
microRNA is incorporated into RISC. It is through this complex that microRNAs 
exert their function upon their target mRNAs [51]. 
The partial or total match of a microRNA with the 3’ untranslated region of 
its target mRNA leads to its post-transcriptional inactivation and/or degradation. It 
is estimated that about 30% of human genes are direct microRNA’s targets which 
Figure 3 – MicroRNA biogenesis and effects. The 
mature microRNA is incorporated in the RISC 
complex and exerts its function by translational 
repression, mRNA cleavage or translational 
activation. Adapted from [3]. 
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implies that microRNAs are involved in mostly all cellular processes including cell 
cycle regulation, cell growth, cellular differentiation and apoptosis [4]. 
Similarly to protein-coding genes, in a normal cell, microRNAs need to be 
tightly regulated in order to maintain a distinct transcriptome signature of a 
particular cell. The loss of this tight regulation has been described in disease, 
including cancer [4]. In the last few years microRNAs became a major focus in 
cancer research with many studies demonstrating their importance in cancer 
biology and the impact of their deregulation in tumor growth, invasion, 
angiogenesis, apoptosis and immune evasion [50]. 
Interestingly, such as tumor suppressing genes and oncogenes, the location 
of a particular microRNA in the genome has consequence on its role in cancer. It 
has been found that many microRNAs are located in chromosomal loci prone to 
deletions or amplifications. As such, a microRNA that negatively regulates a tumor 
suppressor gene may be amplified causing silencing of its target. Conversely, 
microRNAs that repress oncogenes tend to be located in fragile loci and their 
mutation, methylation or deletion results in reduced microRNA expression and 
overexpression of respective target oncogenes [3]. Different tumors appear to have 
particular microRNA profiles and some of these were already reported as being able 
to discriminate tumor subtypes and to correlate with survival and treatment 
response [50]. 
Although the whole mechanism underlying microRNA deregulation in cancer 
is not fully understood, it is known that DNA methylation is involved in the 
regulation of microRNA expression. New technologies have enabled comprehensive 
analysis of the epigenome and as a consequence, the list of microRNAs silenced by 
methylation in cancer is growing rapidly. Indeed, many families of microRNAs have 
already been described as being silenced by methylation, including the miR-124, 
miR-34, miR-9, miR-200 and miR-205 families [52]. In PCa, several microRNAs are 
known to be hypermethylated. Among them is the miR-34 family, miR-126, miR-
193b, miR-145, miR-205, miR-21, miR-615 and miR-196b. MiR-34a appears to play 
an important role in metastasis and is also a target of p53. MiR34b/c targets 
DNMT1 and several histone deacetylases, besides MYC, CDK4, CDK6 and MET (a 
proto oncogene). MiR-145 is downregulated in about 81% of PCa. Its methylation 
has been shown to prevent p53 from binding to miR-145 promoter and regulate 
this microRNA expression [40]. 
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The introduction of biomarkers for cancer diagnosis and disease 
management has revolutionized modern oncology. Biomarkers are molecules 
whose detection or quantitation may be used to interpret the disease and its 
behavior, beyond the traditional clinical parameters [53, 54]. Proteins, metabolites, 
DNA, RNA and epigenetic alterations are all potential candidates to become disease 
biomarkers [54].  
Biomarkers may serve different roles. Currently, there are broadly seven 
different roles for biomarkers, depending on their use and the kind of questions 
they may help answering: disease predisposition, screening, diagnostic, 
prognostic, predictive, monitoring and pharmacogenomics. Concerning this work 
and PCa management current issues, two roles are of particular interest: diagnostic 
and prognostic. Biomarkers that are included in the former role help distinguishing 
patients that have cancer from those who do not harbor this malignancy. On the 
other hand, prognostic biomarkers assist in foreseeing the clinical outcome of a 
patient if therapy is not administered and therefore are useful in disease 
management decisions [53].  
The ideal marker is defined by its specificity to a given kind of pathological 
entity and its high sensitivity while providing advanced warning, ahead of an 
eventual clinical diagnosis. Also, the detection test should be cheap and non-
invasive in order to allow patient screening and be acceptable by the majority of 
the patients [55]. The biomarker should also improve decision-making abilities in 
conjunction with clinical and pathological parameters. It would be ideal to find a 
biomarker that fulfills all of the aforementioned requirements, however, in order 
to cover screening, diagnosis, prognosis and prediction to treatment, multiple 
biomarkers are typically required [53]. 
The use of biomarkers in PCa management, in contrast to most other types 
of cancer, has a long history. The first biomarker found was prostatic acid 
phosphatase which was noted, in 1930, to be elevated in the serum of patients with 
metastatic PCa. PAP remained in use until the 1980’s when it was replaced by 
Prostate specific antigen [53]. 
PSA has been the most commonly used marker for diagnosis and follow-up. 
Until recently, this marker was considered as the most reliable to predict PCa [55]. 
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The introduction of the PSA test, a highly accessible blood test, has revolutionized 
PCa diagnosis in the last three decades [21]. PSA is a kallikrein-related serine 
protease produced in normal prostate secretions [21]. In normal conditions, only 
low levels of PSA can be detected in blood and increased levels are associated with 
abnormalities in the normal architecture of the gland. A blood PSA level higher than 
4.0ng/mL is considered an indication for PCa [53, 55]. Since the advent of PSA, PCa 
prevalence in the USA has more than doubled [24]. 
However, PSA screening has fallen under controversy since it detects 30-50% 
of BPH but just about 20% of the PCa cases. At the same time, evidence has arisen 
that patients harboring PCa may present PSA levels below 4.0ng/mL and that PSA 
levels may rise with other afflictions such as prostatitis and urinary tract infection. 
Also, some drugs used to treat BPH are known to cause a reduction of PSA in the 
blood [55]. 
One of the hard lessons in biomarker design learned with the popularization 
of PSA as a screening test is that biomarker design requires a priori deliberations 
of the intended role [53]. PSA was, initially, thought only as a monitor for PCa 
recurrence but its use was quickly extended to the screening of asymptomatic men 
resulting in overdiagnosis and overtreatment of potentially indolent cancers [53, 
55]. Nevertheless, PSA testing remains in use, since it is inexpensive and sensitive 
(but not specific) for disease detection as well as for monitoring progression and 
recurrence after curative therapy of localized disease [53]. 
Due to the aforementioned limitations of PSA, the search for additional 
biomarkers that supplement or substitute PSA is a very active field of research. This 
is reflected by the number of currently available biomarkers in addition to the 
number of ongoing studies in this field that constantly bring up new potential 
candidates. 
Currently, two FDA-approved PCa biomarkers are available: Prostate Health 
Index (phi) and Progensa PCA3 assay. The Prostate Health Index consists in a 
mathematical formula, -(p2PSA/fPSA) × PSA½, of three biomarkers: the [2] Pro-PSA 
(p2PSA), free PSA (fPSA) and PSA. p2PSA is a molecular form of free PSA suggested 
to be associated with PCa and to be more specific allowing for a better 
discrimination of PCa from BPH than PSA levels [56]. The main intention of this test 
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is to distinguish PCa from benign prostatic conditions in men with more than 50 
years of age and a total serum PSA between 4.0 and 10.0 ng/mL with negative DRE. 
This test also appears to be an independent predictor of biochemical relapse [57]. 
Lazzeri et al., with a small cohort, indicated that phi outperformed tPSA and %fPSA 
with AUC values of 0.73, 0.55 and 0.60, respectively [58]. 
Regarding PCA3, the other FDA-approved PCa biomarker, is a long non-
coding RNA whose expression has been found to be elevated in 90% of PCa tissues, 
but is only slightly expressed in normal or BPH tissues and, contrary to PSA, its 
values are not influenced by the size of the gland [53]. The Progensa PCA3 assay 
uses post DRE urine specimens and consists in an in vitro amplification test 
measuring the concentration and then calculating the ratio of PCA3 RNA molecules 
to PSA RNA molecules originating the PCA3 score. Since its approval by FDA in 
2012 it has been used as a diagnostic test for PCa in the setting of suspect PSA 
levels, negative DRE and/or a previous negative prostate biopsy [53]. Different 
studies provided AUC values ranging from 0.66 to 0.75, sensitivity from 53-69% 
and specificity between 71-83% [56]. 
The following tests are not yet approved by the FDA but are offered under a 
laboratory’s CLIA certificate meaning that these tests are required to demonstrate 
certain performances from an analytical standpoint but their validation is far more 
limited than what is required for regulatory approval. Therefore, validation extent 
of the exposed tests is highly variable [56]. 
The advances of DNA sequencing and transcriptome profiling shifted 
biomarker research towards these “-omics” methods. A promising biomarker in this 
field is the presence of TMPRSS2-ERG gene fusions. These genetic events are among 
the most common alterations in PCa, accounting for 90% of all gene fusions. These 
fusions are highly specific (93%) and can even be detected in precursor lesions such 
as PIN. However, TMPRSS2-ERG is absent in about 50% of PCa cases leaving its 
potential use reduced and only being useful in conjunction with other biomarkers 
as in Mi-Prostate Score [53, 54]. Mi-Prostate Score is an attempt to combine the 
high specificity of TMPRSS2-ERG fusions with PCA3 and PSA measurements [56]. A 
study by Salami et al. although with a limited series of patients showed an AUC 
value of 0.88, 90% specificity and a 80% sensitivity [59]. 
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Oncotype DX is a multi-gene assay designed to be used in small FFPE 
samples obtained by needle-biopsy. This assay measures the expression of 12 
genes, representing four different biological pathways: androgen pathway (AZGP1, 
KLK2, SRD5A2, and RAM13C); cellular organization (FLNC, GSN, TPM2, and GSTM2); 
proliferation pathway (TPX2); and stromal response (BGN, COL1A1 and SFRP4 in 
addition to five reference genes [56]. The expression levels of these genes are then 
combined to calculate the Genomic Prostate Score which is an independent 
predictor of aggressive disease and, recently, showed promise by independently 
predicting biochemical relapse [60, 61]. 
The Prolaris test measures the expression of 31 cell cycle progression genes 
and 15 housekeeping genes to stratify disease risk of progression [56, 62]. It was 
designed to be used in paraffin-embedded specimens and it was found that lower 
expression levels are associated with low risk of disease progression and higher 
levels with increased risk [56]. 
Another multi-gene assay is Decipher, which was developed to assess 
disease progression risk after RP. This assay evaluates the RNA expression levels 
of 22 genes involved in multiple biological pathways implicated in the development 
and progression of PCa. Four studies reported the usefulness of this gene panel to 
predict biochemical recurrence, metastatic progression and disease-specific 
survival after RP [62]. Moreover, in a study using multivariate model this panel was 
the only parameter which correlated with metastatic progression [62]. 
Prostarix is a test designed to aid clinicians in deciding to perform a biopsy 
in patients with a negative DRE and modestly elevated serum PSA levels. It 
measures four metabolites (sarcosine, alanine, glycine, and glutamate) present in 
urine. The urine samples must be collected after a vigorous DRE and liquid 
chromatography–mass spectrometry is performed to acquire the metabolite 
signature which is different between cancer-free tissue and PCa [56]. 
The 4K Score measures PSA isoforms (total PSA, free PSA and intact PSA) in 
addition to hK2. Without hK2, this test uses practically the same isoforms of 
Prostate Health Index [56, 63]. It has been indicated that this score may be useful 
to distinguish indolent from aggressive neoplasms, thus reducing unnecessary 
biopsies and that 4K Score has a better diagnostic performance than PSA 
(AUC=0.83 vs AUC=0.68, respectively) [56]. 
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Some studies have also provided whole-genome information about PCa 
bringing to light some chromosome alterations. Among these, relative 8q gain has 
been proposed as a biomarker for aggressive disease. Indeed, patients with relative 
8q gains had worse prognosis compared with patients harbouring tumors without 
that genetic alteration. Particularly, when stratifying patients according to tumor 
grade or stage, relative 8q gains allowed to discriminate those with poorer outcome 
[54, 64]. 
Another interesting biomarker is α -methylacyl-coenzyme A racemase, 
currently used as a diagnostic ancillary tool in immunohistochemistry. However, its 
prognostic value has not been established so far [54]. Its sensitivity and specificity 
is quite high (>90%) when used as a tissue marker in prostate biopsy. On the other 
hand its potential remains uncertain since it is also significantly expressed in high-
grade prostatic intra-epithelial neoplasia[54]. 
Other potential biomarkers reported by high-throughput proteomics include 
prostate-specific membrane antigen, prostate-specific cell antigen and early 
prostate cancer antigen [53].  
As previously exposed, epigenetic alterations are a common trait in PCa 
lesions and are thought to be highly involved in disease onset and progression. 
Despite their exact roles and full involvement not being yet fully understood, the 
fact that they occur at a higher rate and at an earlier point than mutations makes 
them very attractive biomarkers for diagnosis, prognosis and treatment response 
[65]. 
Since DNA methylation is a tissue-specific trait as well as a tumor-specific 
one, its potential as a biomarker has also been extensively explored. Contrarily to 
protein biomarkers, methylated genes appear to have a higher specificity for 
cancer. This superior specificity is even more noticeable when using blood or other 
biological fluids that are the most attractive clinical samples to be analyzed using 
biomarkers [66]. 
From a practical standpoint, DNA methylation is an interesting alteration for 
laboratory testing since it is far more stable and easier to work with than RNA and 
its isolation and detection is rather straightforward. It can be isolated from most 
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specimens used in the clinic: from formalin fixed tissues to biological fluids that 
can be easily collected, such as urine and blood [67]. Its analysis is possible by 
digestion with restriction enzymes or bisulfite treatment. The latter in particular 
opens many possibilities by PCR based techniques like MSP, either using 
methylation-specific primers or methylation-specific probes; Pyrosequencing and 
bisulfite sequencing [67]. 
The most well studied methylation biomarker in PCa is GSTP1 [68]. This was 
one of the first genes found to be silenced in PCa. GSTP1 encodes an enzyme that 
catalyzes the conjugation of hydrophobic and electrophilic compounds with 
reduced glutathione, acting as a detoxifying agent. Promoter hypermethylation of 
this gene does not occur in normal prostatic tissue nor in BPH. On the other hand, 
it has been detected in PIN lesions [40]. GSTP1 is methylated in more than 90% of 
PCa cases being a particularly promising biomarker for early detection. Assays have 
been developed achieving high specificity for PCa (86-100%). However, sensitivity 
is highly variable depending both on the detection method used and the sample 
type: urine (19-83%) and serum or plasma (13-72%) [69]. Other interesting 
methylation biomarkers in PCa include promoter hypermethylation of APC, 
RASSF1A and RARβ2 [65, 70]. 
Besides being involved in familial adenomatous polyposis, APC is also a well-
known tumor-suppressor gene involved in the Wnt signaling transduction pathway 
and cellular adhesion. This gene is a well-known gatekeeper, preventing the 
transcription of products that lead to cell proliferation and survival. 
Hypermethylation of this gene causes the cell to become more vulnerable to 
additional epigenetic and genetic changes. Although APC promoter methylation is 
common in many malignancies, particularly in colon cancer, previous studies have 
found this gene to be involved in PCa progression and it is hypermethylated in 22-
100% of PCa cases but only in 5-6% of noncancerous prostate tissues [71]. 
Moreover, it was demonstrated to be an independent prognostic factor for worse 
outcome [72]. 
The RASSF1A gene belongs to the RAS proto-oncogenes family. Although 
these are well-known to be involved in signal transduction pathways involved in cell 
proliferation and survival, RASSF1A is a tumor-suppressor gene, known by its 
association with DNA repairing proteins and apoptotic effect [71]. Initially, no 
promoter methylation of RASSF1A was found in benign prostate tissue. More 
recently, it has been found in PIN and benign prostatic epithelium [68]. RASSF1A 
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promoter hypermethylation has been observed in 60-74% or 23-99% of PCa tissues, 
according to different sources, besides being clearly associated with aggressive 
cancers [68, 71]. 
Another interesting biomarker for prostate cancer is promoter 
hypermethylation of RARβ 2, a tumor-suppressor gene. Its expression is 
downregulated or absent in many tumor tissues and its promoter is 
hypermethylated in many tumors as well, including those of the prostate. 
Methylation frequencies in PCa vary according to different studies, ranging from 
22% to 98%. However, it is rarely hypermethylated in normal tissue or in BPH [73]. 
Interestingly, frequencies of 34-62% were observed in urine, and 39-70% in blood 
samples, making it an interesting non-invasive biomarker for PCa [71]. A high 
methylation level of this gene has also been reported as is associated with a 
biochemical recurrence after radical prostatectomy [74].  
Panels comprising two or more methylated genes have been proposed. For 
instance, Hoque et al. proposed a panel with methylation status from RASSF1A, 
RARβ2 and APC, in conjunction with GSTP1 [66]. Moreover, methylation-based 
laboratory-developed tests, not FDA-approved, are currently available. ConfirmMDx 
uses methylation analysis of GSTP1, APC and RASSF1A to detect an epigenetic field 
[62]. Its aim consists in distinguishing patients with a true negative biopsy from 
those who may have occult cancer [56]. This test achieved NPV of 90% and 88% in 
two different studies and showed to be the most significant predictor of biopsy 
results [62].  
Another proposed test that comprises methylation analysis of a panel of 3 
genes is ProCaM, developed by Baden et al. In this study, GSTP1, RARβ 2 and APC 
promoter methylation levels were analyzed in urine samples of patients with serum 
PSA levels between 2.0 and 10.0 ng/ml. AUC values for each marker ranged from 
0.63 to 0.68. When used in conjunction, the three markers yielded an AUC value of 
0.73, sensitivity of 60% and specificity of 80% [75]. Importantly, this assay displayed 
higher predictive accuracy than currently used parameters to decide a prostate 
biopsy and identifies a larger number of cases with high Gleason score [75]. 
As was previously mentioned, microRNAs are known to be silenced by DNA 
methylation in PCa. Therefore, the utility of microRNA promoter methylation as 
potential PCa biomarker has been also studied. A study by Shimizu et al. sought to 
determine a panel of four methylated microRNAs to detect bladder cancer with 
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interesting results: 81% sensitivity and 89% specificity and AUC=0.916 [76]. 
Moreover, it was reported that hypermethylation of miR-34b/c in normal gastric 
mucosa was an independent risk predictor of metachronous gastric carcinoma [77], 
whereas miR-148a was found to be an independent prognostic/predictive 
biomarker in advanced colorectal carcinoma treated with conventional 
chemotherapy [78]. In PCa, hypermethylation of the GABRE∼miR-452∼miR-224 
locus was able to discriminate normal tissues adjacent to tumors from prostatic 
tumors with 94.3% specificity and 95.5% sensitivity (AUC=0.98) [79]. MiR-205 is 
another microRNA that is known to be hypermethylated in PCa. Hulf et al. explored 
its role in PCa carcinogenesis as well as its potential as a biomarker reporting that 
it is a significant predictor of biochemical relapse in patients with low preoperative 
PSA levels [80]. 
Similarly to other epigenetic mechanisms, aberrant patterns of histone 
modifications are a hallmark of cancer and as such, their potential as disease 
biomarkers has started to be unveiled. For instance, in PCa altered levels of 
dimethyl-K4 and acetyl-K18 of histone H3 have been proposed as markers of high-
risk of recurrence [81]. Barlesi et al. reported that high dimethyl-H3K4 or low acetyl-
H3K9 levels have been related with better survival in non-small cell lung carcinoma 
[82]. Also, Barbisan et al. used global acetyl-H3K9 levels to identify patients with 
low-grade bladder cancer who experienced disease recurrence after transurethral 
resection of the bladder [83].   
Because histone modification patterns are altered in cancer in general, and 
in PCa in particular, the enzymes that establish and maintain these patterns it is 
reasonable to consider that these are also deregulated in malignanat cells [84, 85]. 
The best demonstration is provided by EZH2, a methyltransferase, which in PCa 
was shown to better predict tumor progression than serum PSA or Gleason score. 
Moreover, its expression in organ-confined PCa was reported to correlate with risk 
of biochemical recurrence [85]. LSD1, which is a demethylase, is another histone 
modifier with prognostic value, since higher levels were associated with shorter 
time to cancer relapse [86]. However, the role of histone modifications in PCa is 
still not fully understood and their potential as prognostic and diagnostic 
biomarkers is not fully explored. 
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An emerging and exciting field in prostate carcinogenesis field of research, 
different studies showed that microRNAs may be potential diagnostic and 
prognostic biomarkers for PCa. These non-coding RNAs are tissue and tumor-
specific, stable and detectable in body fluids [56]. Several microRNAs have been 
described as being altered in PCa and different expression profiles allow 
differentiation between benign and malignant conditions [87]. 
For instance, miR-141 expression levels were found to be highly increased 
in the sera of men harboring metastatic PCa, predicting the presence of neoplasms 
with 60% sensitivity and 100% specificity. Different studies confirmed this finding 
and thus miR-141 appears to be a suitable biomarker of metastatic progression 
[88, 89]. MiR-21 showed higher expression levels in patients with hormone-
resistant PCa and patients with androgen-sensitive metastatic disease. Moreover, 
in the hormone resistant group, miR-21 levels were higher in patients with 
docetaxel resistance [88]. In another study, miR-375 and miR-141 were found to 
be associated with pathological stage and Gleason score [54, 65].  
Several other studies have reported some microRNAs with diagnostic and 
prognostic value most of which require validation in larger cohorts. Due to their 
interesting performances so far, stability and ease of collection, we may admit that 
microRNA biomarker potential is yet to be fully realized [79]. 
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The PSA-era has brought lasting changes in the study of how biomarkers 
should be designed and used. Although an early diagnosis of PCa is important, 
from a clinical point of view, the high prevalence of indolent cancers detected by 
PSA testing requires surrogate biomarkers able to define clinically significant 
disease. Ideally, PCa biomarkers should reduce the need for biopsy while helping 
to stratify patients according to disease significance which, in turn, may lead to a 
reduction in radical prostatectomies and radiotherapy. 
DNA methylation is a highly specific tissue trait. Therefore, it encompasses 
a promising value as a cancer biomarker, including PCa. MicroRNA deregulation is 
known to be an early event in carcinogenesis and one of the mechanisms 
underlying this deregulation is aberrant DNA methylation. Moreover, since 
epithelial prostatic cells, normal or neoplastic, are often shed in urine, PCa-specific 
biomarkers can be easily tested in that bodily-fluid obtained by non-invasive 
procedures. 
This study is integrated in a broader project which aims to uncover how 
microRNAs’ deregulation contributes to prostate carcinogenesis. Therefore, its 
design was based on preliminary results obtained in that context. 
Specifically, the aims of this master’s dissertation were: 
- To assess promoter methylation status of newly identified microRNAs in 
prostate cancer to determine: 
a) Its potential as prostate cancer biomarkers in tissue samples; 
b) Its performance as biomarkers for early detection in urine samples; 
c) Its prognostic value in biopsy samples. 
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As part of another study of our group, epigenetically regulated microRNAs 
were previously investigated. For this, tissue samples (5 controls and 25 tumors) 
were used for gene methylation profiling using HumanMethylation450 BeadChip 
(Illumina, USA). 
DNA samples were assessed for integrity, quantity and purity by 
electrophoresis in a 1.3% agarose gel, PicoGreen quantification assay and nanodrop 
measurements. 
All samples were distributed into 96-well plates. Bisulfite conversion of 500 
ng of genomic DNA was performed using EZ-96 DNA Methylation-Gold Kit (Zymo 
Research, USA) following manufacturer’s instructions. About 200ng of bisulfite-
converted DNA was used for hybridization using HumanMethylation450 BeadChip 
(Illumina, USA). Briefly, samples were whole genome amplified followed by an 
enzymatic end-point fragmentation, precipitation and resuspension. The 
resuspended samples were hybridized onto the BeadChip for 16h at 48°C and 
washed. A single nucleotide extension with labeled deoxy-nucleotides was 
performed, and repeated rounds of staining were applied with a combination of 
labeled antibodies differentiating between biotin and 2,4-dinitrophenol. Color 
balance adjustment and quantile normalization were performed in order to 
normalize the samples between the two color channels. DNA methylation level is 
displayed as beta-values ranging from 0–1. Beta-values with detection P-value > 
0.01 are considered to fall below the minimum intensity and threshold and were 
consequently removed from further analysis. 
To identify consistently differentially methylated CpG sites Wilcoxon rank 
sum paired test was performed for normalized beta-values. The p-values were 
adjusted using false discovery rate, and those CpGs with p-values <0.05 were 
selected. 
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For this study, 180 PCa samples were prospectively collected from patients 
with clinically localized disease consecutively diagnosed and submitted to radical 
prostatectomy with curative intent from 2001 to 2006, in IPO-Porto Francisco 
Gentil. Control samples, totaling 15, were collected from cystoprostatectomy 
specimens from patients with bladder cancer not harboring PCa. After surgical 
resection and examination, samples were immediately frozen at -80°C. 
Histological examination of the specimens was performed by a pathologist 
in histological slides obtained from formalin-fixed paraffin-embedded tissues of 
these specimens for assessment of Gleason Grade and TNM staging. Other relevant 
clinical data was collected from clinical charts. 
Furthermore, samples from prostatic biopsies from 74 patients were 
collected from individuals referred to IPO-Porto Francisco Gentil due to elevated 
PSA levels, from 2001 to 2003. In addition to the standard diagnostic cores, two 
tissue core samples were collected from the most suspicious areas and fresh-frozen 
at -80°C. Frozen sections with 5 μm were cut and stained and histological evaluation 
was performed by an experienced pathologist. 
Urine samples were collected from 95 patients diagnosed with PCa, before 
being submitted to radical prostatectomy, from 1999 to 2002. Control samples 
were collected from 46 healthy donors. 
Collected samples were centrifuged at 4,000 rpm for 20 minutes and washed 
in PBS 1X. The supernatant was discarded and the procedure was repeated. Pellets 
were re-suspended in 1mL of PBS 1X and centrifuged again at 4,000rpm for 5 
minutes. The pellets were then frozen at -80°C. 
All patients enrolled signed an informed consent and this work was 
approved by the institution review board (CES-IPOFG-EPE 019/08 and CES-IPOFG-
EPE 205/2013) of IPO-Porto Francisco Gentil. 
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DNA was extracted by phenol-chloroform method, with minor variations 
between fresh-frozen tissues and urine pellets. From the fresh-frozen tissues, 15 
μm sections were cut and transferred to 15mL tubes. Then 2,700 mL of SE buffer 
(75mM NaCl and 25 mM EDTA), 300 μL of 10% SDS and 25 μL of proteinase K 
(Genaxxon bioscience, Germany) were added. Samples were incubated overnight at 
55°C. After this period, digestion was prolonged according to necessity with 
subsequent addition of Proteinase K at every 12h until complete digestions was 
achieved. 
Urine samples were first centrifuged at 13,000 rpm for 5 minutes after which 
any remaining supernatant was removed and the pellet re-suspended in 500μL of 
SE buffer. Digestion was achieved by further adding 30μL of SDS at 10% and 15μL 
of Proteinase K at 20 mg/mL and incubating samples at 55°C until digestion was 
complete.  
Following digestion, all samples were transferred to Phase Lock Light 2mL 
tubes (5 Prime, Germany) previously centrifuged at 12,000 rpm for 5 minutes, and 
mixed with 500μL of PC8 (Sigma-Aldrich, USA). 
After centrifugation, at 13,000 rpm for 15 minutes, the aqueous phase was 
transferred to new Phase Lock Light 2mL tubes previously centrifuged and 500μL 
of PC8 were added followed by another centrifugation. 
DNA precipitation was accomplished by transferring the aqueous phase to 2 
mL tubes and adding 1 mL of cold absolute ethanol, 135 μL of ammonia acetate at 
7.5M and 2 μL of glycogen. After mixing, samples were left at -20°C overnight. 
Posteriorly, samples were washed in ethanol 70%, the pellets air dried and 
then eluted in 30 μL (tissue samples) and 20 μL (urine samples) of sterile distilled 
water. DNA concentration and purity were assessed using NanoDrop Lite 
Spectrophotometer (Nanodrop Technologies, USA) and stored at -20°C until further 
use. 
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Sodium bisulfite modification of DNA is the basis of methylation studies 
involving sequencing and PCR. By this process, DNA is firstly denatured and, as 
displayed in Figure 4, unmethylated cytosines are sulfonated giving origin to a 
cytosine sulfonate, then deaminated and finally desulfonated, thus losing the 
bisulfite group and, finally, becoming uracils. Since methylated cytosines resist this 
modification, discrimination between methylated and unmethylated cytosines 
becomes possible [2]. 
 
Genomic DNA from all samples used was modified by sodium bisulfite using 
EZ DNA Methylation-Gold™ Kit (Zymo Research, USA) according to the 
manufacturer’s guidelines. From DNA obtained from frozen tissues, 1 μg of DNA 
was used. Due to the scarcity of the material, the used quantity of DNA extracted 
from urine samples was adjusted to 500 ng. 
The required volume of DNA was diluted in sterile water to a total volume of 
20 μL in a PCR tube, according to the specified concentration of each sample. To 
each sample, 130 μL of CT Conversion Reagent was added and then incubated in a 
GeneAmp PCR System 2700 thermal cycler (Applied Biosystems, USA) at 98°C for 
10 minutes and then at 64°C for 3 hours. 
Once finished the incubation, samples were transferred to a Zymo-Spin IC 
column with 600 μL of M-binding buffer and centrifuged at 10,000 rpm for 30 
seconds. After being washed with 100μL of M-Wash buffer and again centrifuged 
at 10,000 rpm for 30 seconds, desulphonation was achieved with an incubation at 
room temperature with 200 μL of M-Desulphonation buffer for 20 minutes. M-
Figure 4 - DNA modification by sodium bisulfite. Cytosine is deaminated becoming 
uracil while methylcytosine resists this treatment. Adapted from [2].. 
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Desulphonation buffer was discarded following a centrifugation at 10,000 rpm for 
30 seconds. Then two washings were carried out with 200 μL of M-Wash buffer 
followed by centrifugations at 10,000 rpm for 30 seconds. 
Finally, the collumn was placed in a 1.5mL tube and DNA was elluted by 
incubating with 60 μL of M-Elution buffer for 5 minutes at room temperature 
followed by a centrifugation at 10,000 rpm for 30 seconds. The modified DNA was 
stored at -80°C until further use. 
One μg of CpGenome™ Universal Methylated DNA (Millipore, USA) was also 
modified, according to the method described above and eluted in 30μL of M-elution 
buffer. 
 
To assess methylation levels, quantitative real-time methylation specific PCR 
was performed in all samples using KAPA SYBR FAST qPCR Kit Master Mix. The 
modified DNA was used as template and samples were submitted to reactions with 
the target genes: miR-34b/c, miR-129-2, miR-152, miR-193b, miR-663a and miR-
1258; as well as the reference gene, ACTβ. 
Reactions were carried out in 384-well plates using LightCycler 480 II (Roche, 
Germany). Briefly, per each well 1 μL of modified DNA and 5 μL of 2X KAPA SYBR 
FAST qPCR Master Mix were added. The volume of primers used varied (according 
to Table 3) and sterile distilled water was added in order to total 10 μL of reaction 
volume. 
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Table 3 - Primers sequences used and qMSP conditions for each of the tested candidates. 
   
  
β 
TGGTGATGGA
GGAGGTTTAG
TAAGT 
AACCAATAAAA
CCTACTCCTCCC
TTAA 
60 0.4 μL 
 
GTTTAGTTACG
CGTGTTGTGC 
CGAAAAACGCC
CTACCATA 
60 0.3 μL 
 
CGGCGAATCG
AAGAAGTC 
TACGCCCTCCG
CAAATAC 
62 0.4 μL 
 
TCGTCGTTCG
GGATTTTC 
ACTAACCACGT
CCGCACC 
62 0.4 μL 
 
AGCGGGGTGT
TTGTGTTC 
AAACATAAACG
ACGCATTCCA 
62 0.2 μL 
 
GGGATAGCGA
GGTTAGGTC 
CATTCGTAACG
AATAAAACCC 
60 0.3 μL 
 
TCGGTATATTT
GGCGGAGTC 
TCCGACGAAAA
TAAACCCC 
60 0.3 μL 
 
The PCR program consisted of a period of 3 minutes at 95°C for enzyme 
activation followed by 45 cycles with 3 seconds at 95°C (for DNA denaturation) and 
30 seconds at 60°C (for annealing, extension and data acquisition). 
All samples were run in triplicates and in each plate one negative template 
control was run. Modified CpGenome™ Universal Methylated DNA was used to 
create five serial dilutions by a 5x dilution factor. These serial dilutions were run in 
each plate and were used to generate a standard curve thus allowing absolute 
quantification as well as ascertaining PCR efficiency. All plates had an efficiency 
between 90-100%. 
Methylation levels were calculated as a ratio between the target gene mean 
quantity and ACTβ mean quantity: 
 
Methylation level =
Target gene mean quantity 
ACTβ mean quantity 
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Non-parametric tests were performed to determine statistical significance in 
all the comparisons made. In particular, Kruskall-Wallis test was used in 
comparisons between 3 or more groups, whereas Mann-Whitney U test was used 
for comparisons between two groups. Survival function was performed to evaluate 
correlation between methylation levels and disease specific survival. Logistic 
regression models were also built in order to evaluate the potential of using the 
targets as a panel to increase performance. Spearman nonparametric correlation 
test was performed to correlate methylation levels with patients’ serum PSA. 
Statistical significance was set at P<0.05. Bonferroni’s correction was applied to 
pairwise comparisons.  
When assessing the targets’ performance as biomarkers, ROC curves were 
built. Moreover, biomarker parameters [specificity, sensitivity, positive predictive 
value, negative predictive value and accuracy] were determined using the formulas 
provided in Table 4. For this, the cut-off established was the highest value obtained 
by the ROC curve analysis (sensitivity + (1-specificity)). 
Statistical analysis was performed using SPSS Statistics 20 (IBM, USA). 
Graphics were assembled using GraphPad 5 Prism (GraphPad Software, USA). 
Table 4 - Formulas used for biomarker parameters calculation. 
(C/A) x100 
(F/B) x 100 
A B (C/(C+D)) x 100 
C D (F/(E+F)) x 100 
E F ((C+F)/(A+B)) x 100 
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For the purposes of this study, clinical samples (tissues and urine) from 
different patient cohorts were collected. The relevant clinical and pathological data 
are depicted in Tables 5 and 6.  
Table 5 – Clinical and pathological data of all the PCa samples used in this study.  
MNPT PCa 
Healthy 
donors 
PCa PCa 
15 180 46 95 74 
63 
(45-80) 
65 
(49-74) 
61 
(58-77) 
64 
(45-80) 
68 
(49-85) 
- 
8.30 
(3.4-23) 
- 
8.80 
(3.5-20.4) 
18.22 
(4.52-542) 
 
- 96 (53.3) - 46 (48.4) 48 (64.9) 
- 84 (46.7) - 49 (51.6) 12 (16.2) 
- - - - 14 (18.9) 
- 56 (31.1) - 37 (39.0) 30 (40.5) 
- 108 (60) - 50 (52.6) 33 (44.6) 
- 16 (8.9) - 8 (8.4) 11 (14.9) 
- 50 (28) - 24 (25) 32 (43) 
- 9 (5) - 4 (4) 17 (23) 
MNPT - morphologically normal prostatic tissue; PCa - prostate carcinoma 
 
Table 6 - Number, age and gender of vesical and renal tissue samples 
used as controls in this study. 
9 43 9 50 
61 
(52-75) 
63 
(43-83) 
64 
(20-83) 
63 
(37-83) 
 
9 (100) 
- 
 
36 (83.7) 
7 (16.3) 
 
6 (66.7) 
3 (33.3) 
 
29 (58) 
21 (42) 
NBl – normal bladder; BlCa - bladder carcinoma; NK - normal kidney; 
RCT - renal cell tumor. 
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As part of an ongoing PhD thesis project, aiming at the discovery and 
characterization of new epigenetically regulated microRNAs in PCa, results from 
the analysis of a HumanMethylation450 BeadChip array were used. This array is 
designed to evaluate thousands of methylation sites across the genome. The most 
differentially methylated CpGs observed in known microRNA promoter regions 
were depicted for miR-34b/c, miR-129-2, miR-152, miR-193b, miR-663a, and miR-
1258 (Figure 5).  
 
Figure 5 - HumanMethylation450 BeadChip results. The microRNAs displayed showed the 
most significant differences between MNPT and PCa samples were selected for further 
analysis. 
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After primer design and optimization, validation of the selected candidate 
microRNAs was achieved using qMSP assays to assess the methylation levels in 
MNPT and PCa samples for each. 
In accordance with the array’s results, all microRNAs tested showed higher 
promoter methylation levels in PCa compared to MNPT. Because our first goal was 
to discover novel microRNAs fit for PCa detection, ROC curve analysis was 
conducted in the validation cohort (Figure 6) and an empirical cut-off value was set 
for each microRNA. 
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Figure 6 - Box-plots (left panel) depicting higher promoter methylation levels in PCa tissues 
compared to normal prostatic tissues and ROC curves (right panel) displaying high 
biomarker performance, in all candidates tested.  
 
The standard validity and information estimates for each microRNA were 
also calculated to further characterize its performance as PCa biomarkers (Table 
7). 
Table 7 - Performance of epigenetic biomarkers for the detection of PCa in RP specimens. 
94.4 (170/180) 86.7 98.8 56.5 93.8 
90.6 (163/180) 86.7 98.8 43.3 90.3 
79.4 (143/180) 86.7 98.6 26.0 80.0 
90.0 (162/180) 100.0 100.0 45.5 90.8 
84.4 (152/180) 100.0 100.0 34.9 85.6 
97.8 (176/180) 100.0 100.0 78.9 97.9 
 
Notably, all candidate microRNAs, except miR-152, displayed AUC values 
above 0.90. In the testing cohort series (tissue samples from prostatectomy 
specimens), miR-1258 showed the best performance with AUC=0.99, 97.8% 
sensitivity and 78.9% NPV, followed by miR-193b, with AUC=0.96 and then miR-
34b/c and miR-663a, both with AUC=0.95, although miR-34b/c showed higher 
sensitivity, accuracy and NPV. 
Additionally, for each microRNA, promoter methylation levels were found to 
be associated with the standard clinicopathologic parameters. As depicted in Figure 
7, higher methylation levels of miR-34b/c, miR-129-2, miR-663a and miR-1258 
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were significantly associated with higher pathological stage. Moreover, increased 
methylation levels of miR-129-2 were also found in less differentiated tumors 
(Gleason Score ≥ 7). Owing to the inferior biomarker performance of miR-152, it 
was not further tested. 
 
   
Figure 7 - Distribution of methylation levels according to Gleason score and pathological stage. 
The candidates displayed had statistically higher methylation levels in samples with higher 
Gleason score and pathological stage. 
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To verify whether the candidate microRNAs were prostate cancer-specific, 
the methylation levels of each microRNA were evaluated in tissue samples from 
other urinary organs tract, namely bladder and kidney, both normal and neoplastic.  
  
  
 
Figure 8 - Distribution of microRNAs’ promoter methylation levels in prostatic, vesical and 
renal tissues. MNPT - morphologically normal prostatic tissue; PCa - prostate carcinoma;             
NBl - normal bladder; BlCa - bladder carcinoma; NK - normal kidney; RCT – renal cell tumor. 
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Since the ultimate goal of this study was to develop an assay powerful 
enough to detect PCa in bodily fluids, namely in urine samples and because both 
kidney and bladder exfoliate cells for urine, it was critical to ensure that 
methylation levels of cells (both normal and neoplastic) shed from those organs 
would not confound our assay. 
Globally, promoter methylation levels of all microRNAs were lower in renal 
tissues (both normal and malignant) compared to PCa samples. However, 
methylation levels of miR-129-2 and miR-663b were significantly higher in BlCa 
than in PCa. Thus, miR-34b/c, miR-193b and miR-1258, were selected for further 
testing in urine sediments as its promoter methylation was shown to be PCa-
specific. 
 
Validation of miR-34b/c, miR-193b miR-1258 was subsequently assessed in 
urine sediments collected from both healthy donors and PCa patients. 
Whereas promoter methylation levels of miR-34b/c and miR-193b were 
significantly higher in urines from PCa patients compared to those from healthy 
donors, the opposite was observed for miR-1258 methylation levels. 
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Figure 9 - Box-plots (left panel) depicting higher promoter methylation levels in PCa patients for 
miR-34b/c and miR-193b (but not for miR-1258) and ROC curves (right panel) displaying miR-
34b/c, miR-193b and miR-1258 biomarker performance across urine sediments. 
 
Table 8 - Performance of epigenetic biomarkers for the detection of PCa in urine sediments. 
89.5 (85/95) 47.8% 78.0% 68.8% 75.9% 
91.6 (87/95) 95.7% 97.8% 84.6% 92.9% 
7.4 (7/95) 43.5% 21.2% 18.5% 19.1% 
 
ROC curve analysis, revealed that miR-193b allowed for a better 
discrimination of PCa from normal samples, compared to miR-34b/c, with AUC 
values of 0.96 vs. 0.71, as well as 91.6% sensitivity and 95.7% specificity vs. 89.5% 
and 47.8% respectively. Although the sensitivity of miR-34b/c was about 90%, 
specificity was below 50%. Remarkably, PPV and NPV values for miR-193b were 
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97.8% and 84.6%, respectively. No statistically significant association between 
microRNAs promoter methylation levels and clinicopathological parameters was 
depicted, in urine samples. 
 
The last aim of this Master thesis consisted on the assessment of the 
prognostic value of microRNA promoter methylation in prostate biopsy tissue 
cores. The median follow-up in this PCa patient cohort was 104.04 months (range: 
9.11–170.10 months). At the time of the last follow-up, 17 patients (22.97%) had 
died from PCa and 32 out of of 74 (43.24%) developed biochemical recurrence. In 
3 patients, serum PSA levels >0.2 ng/ml persisted following treatment and these 
were not further considered for disease-free survival analysis. 
Hence, disease-specific survival (DSS) and disease-free survival (DFS) curves 
were constructed based on clinical variables, namely clinical stage, Gleason score, 
PSA levels and CAPRA Score, to validate our data. Since CAPRA score values range 
from 1 to 10, for the purpose of this analysis this variable was categorized as 0-2 
(low-risk tumors), 3-5 (intermediate risk) and 6-10 (high-risk tumors) [30]. For 
statistical purposes, microRNA methylation levels were dichotomized using the 
percentile 75 as threshold value. Except for serum PSA, all clinicopathologic 
parameters tested and miR-129-2, but not miR-34b/c, methylation levels, 
associated with DSS in univariate analysis. 
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Figure 10 – Higher clinical stage (upper left), Gleason Score (upper right) CAPRA Score (lower 
left) and miR-129-2 methylation levels (lower right) associated with worse disease-specific 
survival curves on a biopsy cohort of 74 PCa patients. 
 
Moreover, a Cox regression analysis was also computed to assess the 
potential of both clinicopathological and epigenetic variables in predicting DSS 
(Table 9). Of the clinicopathological variables, only clinical stage was statistically 
significant. Interestingly, high miR-129-2 promoter methylation levels also 
independently predicted shorter DSS, although with a lower hazard ratio. 
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Table 9 - Cox regression assessing the potential of clinical and epigenetic 
variables in the prediction of disease-specific survival for 74 PCa patients. 
II 1   
III/IV 8.12 2.63-25.1 <0.001 
≤P75 1   
>75 3.30 1.26-8.61 0.015 
 
Because biochemical recurrence is an important primary endpoint in PCa, we 
further tested the prognostic value of standard clinical variables and methylation-
based markers in this setting. 
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Figure 11 – Higher clinical stage (upper left panel), Gleason score (upper right panel) and 
miR-129-2 methylation levels (lower) associated with poorer disease-free survival in a biopsy 
cohort of 71 PCa patients. 
 
PSA levels and CAPRA score did not associate with DFS in univariate analysis. 
Nonetheless, higher clinical stage, Gleason score and miR-129-2 promoter 
methylation levels statistically associated with worse DFS. MiR-34b/c methylation 
levels displayed a trend similar to that of miR-129-2, but did not reach statistical 
significance (P=0.06). 
Similar to DSS, only higher clinical stage and increased miR-129-2 promoter 
methylation levels independently predicted shorter DFS, in multivariate analysis 
(Table 10).  
 
Table 10 - Cox regression assessing the potential of clinical and epigenetic 
variables in the prediction of disease-free survival for 71 PCa patients. 
 
 
   
II 1   
III/IV 2.46 1.20-5.03 0.014 
   
≤P75 1   
>75 2.26 1.08-4.73 0.031 
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PCa remains one of the most prevalent neoplasms worldwide and constitutes 
a leading cause of morbidity and mortality by cancer in men. Due to PSA screening, 
improvements have been achieved in clinical management of this malignancy. 
Indeed, its introduction, not only has led to a lower median age of diagnosis, but 
also to a decrease in the number of men presenting with metastatic disease at the 
time of diagnosis. Conversely, more men have been diagnosed with PCa, most of 
which with indolent tumors, and more men with benign conditions such as BPH and 
prostatitis have been biopsied. Thus, the potential benefits of PSA screening have 
been challenged by overdiagnosis of prostate carcinomas that would not cause 
harm or death if left undiagnosed and untreated [65]. Thus a strong 
recommendation against PCa screening through serum PSA levels has been issued 
recently, prompting the search for more effective biomarkers that allow for 
patients’ risk stratification. In this project, we aimed to contribute to this relevant 
scientific and clinical quest through the discovery of new biomarkers for PCa 
detection and prognostication. For that purpose, we performed DNA methylation 
analysis in multiple patient cohorts and sample types for identification and 
validation of novel PCa biomarkers with improved performance. 
Deregulation of epigenetic mechanisms is a key factor in carcinogenesis. 
Besides providing insight into the complex process that is prostate carcinogenesis, 
DNA methylation analysis has also brought forward valuable detection biomarkers 
for this disease, such as GSTP1, APC, RARβ2 and RASSF1A [69]. Indeed, epigenetic 
silencing of cancer-related genes by aberrant promoter methylation is now 
recognized as a key event in prostate carcinogenesis and a promising tool for 
screening, early diagnosis and prognostication of PCa [40]. Besides gene promoter 
methylation, microRNA deregulation is an acknowledged epigenetic feature of 
cancer. Aberrant microRNA promoter methylation has been recognized as an 
underlying cause of this deregulation in several neoplasms, including PCa [90]. 
Owing to our previous experience in DNA methylation analysis [70, 72, 73], 
we decided to seek for altered methylation patterns at the promoter regions of 
microRNAs deregulated in PCa. This information was then used to develop novel 
biomarkers, instead of microRNA expression levels, as previously attempted by 
others [91-93]. Indeed, DNA methylation is easier to assess than microRNA 
expression, it is more specific and, importantly, more stable. Moreover, because 
microRNAs downregulation in cancer is more common than upregulation, it 
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seemed likely that aberrant promoter methylation might constitute an underlying 
mechanism, similar to protein-coding genes [52].  
Although several strategies might be used to identify microRNAs putatively 
downregulated due to promoter hypermethylation, high-throughput technologies 
such as methylation-array analysis is able to simultaneously pinpoint putative 
candidates [94] and the reliability of the results might be readily assessed through 
the analysis of well-known hypermethylated loci. Indeed, the results of the 
methylation array experiments that gave rise to this dissertation confirmed the high 
prevalence of GSTP1 and APC promoter methylation (data not shown). To increase 
the likelihood of finding robust candidate biomarkers, we used stringent conditions 
based on high fold-variation of methylation levels between cancerous and non-
cancerous tissue samples. Nevertheless, subsequent validation of the results from 
the array are mandatory to definitively assess the performance of the candidate 
biomarkers. 
From methylation-array analysis, six candidate microRNAs, putatively 
deregulated by promoter hypermethylation were identified. Among those, miR-
1258 was the most promising due to very high sensitivity, specificity and accuracy 
in tissue samples. Moreover, it demonstrated substantial PCa-specificity compared 
with other tumors from the urinary tract, a feature that would make it the most 
attractive candidate to test in bodily fluids. MiR-193b was also a very promising 
candidate with a very good performance. Like miR-1258, its methylation seems to 
be very specific for PCa. Finally, miR-34b/c was also considered for testing in urine 
samples since it showed interesting results albeit not as promising as the previous 
two. Although it had better sensitivity and accuracy than miR-193b, its specificity 
was lower than that of miR-193b. Nevertheless, it was also very specific for PCa 
when compared with bladder and renal tissues, either cancerous or non-cancerous. 
MiR-129-2 and miR-663a showed modest results as diagnostic biomarkers but their 
inability to distinguish PCa from bladder cancer rendered them unsuitable to be 
tested in urine samples. 
Correlation between the methylation levels measured by qMSP in the tumor 
tissue samples and standard clinicopathological variables (serum PSA at diagnosis, 
pathological stage, Gleason score) was also assessed for all candidates. In this 
analysis, increased promoter methylation levels of miR-129-2 were associated with 
higher Gleason score and stage, indicating that this microRNA could be a putative 
prognostic biomarker. MiR-34b/c, miR-663a and miR-1258 methylation levels also 
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correlated with pathological stage, but its higher diagnostic performance 
underscores the potential for detecting PCa at early stages instead of prognostic 
assessment, as we previously reported for EFEMP1 promoter methylation [95]. 
Importantly, these results are in line with previous observations by our research 
team and others concerning the association of higher gene promoter methylation 
levels with clinicopathological features of more advanced and aggressive disease.  
The next step consisted in testing the best performing diagnostic candidates 
in urine samples. Urine is a very attractive clinical sample to evaluate DNA 
methylation biomarkers for PCa. It is easily obtainable and biomarkers are diluted 
to a smaller extent than in plasma, providing higher sensitivity [96]. Nevertheless, 
the amount of DNA potentially deriving from prostatic cells is rather variable, 
usually low, entailing the need to use a panel with limited number of biomarkers. 
Thus, only miR-34b/c, miR-193b and mir-1258, were tested in urine samples 
obtained from healthy donors and patients harboring PCa. Mir-193b displayed the 
best results in this assessment, with high AUC, sensitivity, specificity and PPV, 
whereas miR-34b/c performance was modest. Intriguingly, miR-1258, which 
showed the best performance in tissue samples, displayed a strikingly different 
result in urines as its methylation levels were higher in healthy donors’ samples 
than those from PCa patients.  The reason for this discrepant result is not 
immediately apparent, but it could be due to high miR-1258 promoter methylation 
in non-epithelial cells, such as leucocytes that might be relatively more abundant 
in urine than in tumor tissue samples. Moreover, median miR-1258 promoter 
methylation levels in urines from PCa are substantially inferior to those of miR-
193b, thus, impairing the robustness of the qMSP assay. It should be recalled that, 
contrarily to other studies, the urine samples we used were not collected following 
DRE or prostatic massage, which are usually employed in an attempt to yield a more 
representative sample to increase sensitivity. Studies dealing with PCa biomarkers 
in urine  vary in the method of urine collection and the real impact of prostatic 
massage has never been evaluated [97]. It could be argued that the distance from 
the peripheral zone to the urinary tract flow may render urinary based tests less 
sensitive, which would be an important issue since most malignancies arise from 
this zone. Nevertheless, studies on PCA3 did not find a difference in the levels of 
this biomarker between patients with peripheral versus transitional zone PCa [98, 
99]. 
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Interestingly, studies using post-DRE collected urine samples have reached 
different levels of success. GSTP1, RARβ2 and APC promoter methylation levels 
assessed in urine samples collected after DRE showed modest performance as 
biomarkers for PCa detection (AUCs varied from 0.63 to 0.68) [75]. Even GSTP1 
promoter methylation sensitivity in urine differs among reports, from 21.4% to 
38.9%, depending on the assay used, although it is improved by prostatic massage 
to 75% [100]. Moreover, in our study, miR-34b/c and miR-193b had higher 
methylation levels in urine samples from patients with PCa, as would be expected, 
with miR-193b showing better results than those mentioned above for GSTP1, 
RARβ2 and APC. In another study using urine samples following prostatic massage, 
Rouprêt et al assessed methylation levels of several genes (including GSTP1, 
RASSF1A, CDH1, APC, DAPK, MGMT, p14, p16, RARβ2, and TIMP3) by qMSP. Of 
these GSTP1, RASSF1A, APC and RARβ2 were those that best discriminated 
malignant from non-malignant cases, with AUC values ranging from 0.74 to 0.86. 
The combination of these four genes yielded the greatest discriminatory power 
with 86% sensitivity and 89% overall accuracy [101]. Importantly, the diagnostic 
performance of miR-193b in urine compares favorably with the aforementioned 
biomarkers, but it should be tested in a larger and independent dataset. 
Notwithstanding, the performance of miR-193b in urine samples needs to 
be compared with that of serum PSA and urinary PCA3, as these are the only 
biomarkers approved for clinical use. As previously mentioned, the performance of 
serum PSA as a PCa biomarker is rather modest, with AUC ranging from 0.54 to 
0.70 [53, 100]. Even other serum PSA-derived measurements, like PSA-density, free 
PSA percentage and PSA-velocity have not improved this value above that interval 
[53]. On the other hand, PCA3, which is currently the most widely used non-PSA 
based first-line test, performed better that serum PSA, both in urine and ejaculates, 
with AUC varying from 0.66 to 0.79 [53, 100, 102, 103]. Once again, miR-193b 
performance compares well with those two PCa biomarkers and might constitute a 
promising tool for early non-invasive detection of PCa, if these results are 
independently confirmed. It should be emphasized that combining miR-193b with 
miR-34b/c did not increase the diagnostic performance of the assay (data not 
shown). 
The last aim of this study consisted on the determination of the prognostic 
value of the candidate microRNAs. For this purpose, miR-34b/c and miR-129-2 
promoter methylation levels were analyzed in set of prospectively collected 
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prostate biopsies. Because the major goal was to discriminate the clinically 
aggressive PCa from those that do not pose a threat to the patient’s life and might 
be left untreated, it was critical to test the prognostic value of the microRNAs in a 
pre-therapeutic setting. In univariate analysis, most standard clinicopathological 
parameters associated with DSS and DFS, thus clinically validating this prostate 
biopsy dataset.  The CAPRA score, however, only correlated with DSS but not DFS 
in this series. This was an unexpected result as CAPRA score determined at 
diagnosis, correlates with DFS in patients submitted to radical prostatectomy, i.e., 
those with clinically localized disease [30]. Notwithstanding, our prostate biopsy 
series included PCa at diverse clinical stages, submitted to different therapeutic 
modalities: radical prostatectomy, radiotherapy or androgen-deprivation therapy. 
This feature might explain the failure of CAPRA score to predict DFS. In multivariate 
analysis, only clinical stage, amongst all clinicopathological parameters tested, 
retained independent prognostic value, both for DSS and DFS. Remarkably, high 
miR-129-2 promoter methylation levels also predicted shorter DSS and DFS, 
suggesting that it might constitute a useful prognostic biomarker for PCa patients. 
It should be recalled that miR129-2 and miR-34b/c were selected for this analysis 
based on their association with pathological stage or Gleason score in the radical 
prostatectomy cohort. Considering the results of the multivariate analysis in the 
prostate biopsy cohort, we might assume that miR-129-2 promoter methylation 
levels are indicative of more clinically aggressive PCa, irrespective of disease extent 
at diagnosis. 
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In this study we explored the biomarker potential of six candidate microRNA 
that were previously found to be hypermethylated in PCa by our group. 
All candidates were validated in a large RP sample set. Moreover, we tested 
the PCa-specificity of methylation levels from each candidate, in comparison to 
other urinary tissues and neoplasms. Thus, the most promising diagnostic 
biomarkers (miR-34b/c, miR-193-b and miR-1258) were tested in an independent 
set consisting of voided urine samples, in which miR-193b was shown to be a very 
promising diagnostic biomarker with potential use as a non-invasive test for early 
detection of PCa. 
Moreover, those microRNAs whose methylation levels were found to be 
associated with aggressive disease in the validation set (miR-34b/c and miR-129-
2) were tested in a set of biopsy samples, seeking for prognostic value. MiR-129-2 
surfaced as independent predictor of survival as higher promoter methylation 
levels associated with poorer DSS and DFS. 
Although additional studies, preferably involving multiple institutions, are 
required to further validate these findings, we demonstrated herein that 
quantitative assays for specific microRNA promoter methylation (miR-193b and 
miR-129-2) might constitute important diagnostic and prognostic ancillary tools for 
clinical decision making. 
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Table 11 - Current knowledge of the six putative candidates analyzed in this study. 
chr11: 111512938-
111513021 
chr11: 111513439-
111513515 
Promoter polymorphisms increase risk of HCC and 
RCC, and decrease risk in gastric cancer [104-106]. 
Promoter hypermethylation is associated with late 
clinical stage in patients with soft tissue sarcomas 
[107]. 
Promoter methylation in 
stool samples for 
colorectal cancer [108]. 
Downregulated by 
promoter 
methylation [109, 
110]. 
chr11: 43581394-
43581483 
Epigenetically repressed in gastric, esophageal, 
endometrial, lung, colorectal and hepatic tumors 
[90, 93, 111-113]. 
Expression in gastric 
juices [92]. 
Expression in plasma 
for HCC [93].  
Not reported. 
chr17: 48037161-
48037247 
Downregulated in lung, liver, ovarian, laryngeal and 
bladder cancer [114-118]. 
Proposed tumor-suppressor role in NSCLC [119, 
120]. 
Expression 
differentiates high-risk 
from low-risk PCa [91]. 
Promoter is highly 
methylated. 
Has a tumor 
suppressor role 
[121, 122]. 
chr16: 14303967-
14304049 
Downregulated in pancreatic tumors causing 
impaired cell growth [123]. 
Downregulated in ovarian carcinoma promoting 
metastasis [124, 125]. 
High expression correlates with poor survivability in 
melanoma and drives breast cancer progression 
(11). 
Not reported. 
Silenced by promoter 
methylation [126]. 
Has a tumor 
suppressor role 
[127]. 
chr20: 26208186-
26208278 
Downregulated in chordomas and pancreatic tumors 
[128, 129]. 
Expression in serum 
samples for chordomas 
and pancreatic tumors 
[129]. 
Not reported. 
chr2: 179860836-
179860908 
Has a negative correlation with heparanase 
expression and is downregulated in NSCLC and 
breast tumors [130, 131]. 
Not reported. Not reported. 
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